TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the initiation of a Phase 2 clinical trial evaluating BRIUMVI® (ublituximab-xiiy), in adults with treatment-resistant schizophrenia. The Phase 2 ...
Zacks Investment Research on MSN
Will Briumvi's strength continue to aid TGTX's top line in Q2?
TG Therapeutics’ TGTX sole marketed drug, Briumvi (ublituximab-xiiy), has been witnessing strong sales growth since its ...
・Earlier this month, TG Therapeutics reported positive early results for a new under-the-skin version of BRIUMVI in patients with myasthenia gravis. ・Prior to that, the company also released ...
Detailed price information for Tg Therapeutics (TGTX-Q) from The Globe and Mail including charting and trades.
TG Therapeutics TGTX has announced positive top-line data from the late-stage ENHANCE study, which evaluated a consolidated single-infusion regimen of its sole marketed drug, Briumvi (ublituximab-xiiy ...
NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TGTX), announced that it has been awarded a national contract with the Department of Veterans Affairs (VA) for BRIUMVI® (ublituximab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results